5 documents found, page 1 of 1
Hospitalization of symptomatic patients with heart failure and moderate to seve...
Ponikowski, Piotr; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Shahzeb Khan, Muhammad; Diek, Monika; Heinrich, Jutta; Geyer, MartinBackground: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. Objectives: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before ...
Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist th...
Pitt, Bertram; Anker, Stefan D.; Lund, Lars H.; Coats, Andrew J. S.; Filippatos, Gerasimos; Rossignol, Patrick; Weir, Matthew R.; Friede, TimBackground: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). Objectives: This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAA...
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgita...
Anker, Stefan D.; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Khan, Muhammad Shahzeb; Diek, Monika; Heinrich, Jutta; Geyer, MartinAim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results: The RESHAPE-HF...
Patiromer for the management of hyperkalemia in heart failure with reduced ejec...
Butler, Javed; Anker, Stefan D.; Lund, Lars H; Coats, Andrew J. S.; Filippatos, Gerasimos; Siddiqi, Tariq Jamal; Friede, Tim; Fabien, VincentAims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run...
Patiromer for the management of hyperkalaemia in patients receiving renin–angio...
Butler, Javed; Anker, Stefan D.; Siddiqi, Tariq Jamal; Coats, Andrew J. S.; Dorigotti, Fabio; Filippatos, Gerasimos; Friede, Tim; Göhring, Udo‐MichaelAims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screeni...